Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles for Hospitalized Patients With Moderate-to-Severe ARDS: A Phase III Clinical Trial
Latest Information Update: 27 Nov 2024
At a glance
- Drugs DB-001 (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections; COVID-19 respiratory infection
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms EXTINGUISH ARDS; Extinguish Covid-19
- Sponsors Direct Biologics
Most Recent Events
- 19 Dec 2023 Planned End Date changed from 3 Aug 2024 to 31 Aug 2025.
- 19 Dec 2023 Planned primary completion date changed from 3 Mar 2024 to 31 Mar 2025.
- 19 May 2023 Planned number of patients changed from 320 to 970.